Nakamura Tsutomu
Dept. of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Gan To Kagaku Ryoho. 2004 Mar;31(3):322-6.
Barrett's esophageal adenocarcinoma arises in Barrett's epithelium, which is grouped with gastro-esophageal reflux disease (GERD). Although the incidence of esophageal adenocarcinoma is very low in eastern countries, including Japan, it has been increasing markedly and is similar to that of squamous cell carcinoma in the western countries. Surveillance, endoscopic treatment, and chemoprevention using COX-2 inhibitors have recently been developed for dysplasia or mucosal cancer in Barrett's esophagus. Barrett's esophageal adenocarcinoma is diagnosed by endoscopy and by biopsy specimens pathologically. Surgical resection has been a mainstream treatment but definitive or neoadjuvant chemoradiotherapy has recently been performed.
巴雷特食管腺癌起源于巴雷特上皮，巴雷特上皮与胃食管反流病（GERD）相关。尽管在包括日本在内的东方国家，食管腺癌的发病率很低，但它一直在显著上升，且在西方国家与鳞状细胞癌的发病率相似。最近已针对巴雷特食管的发育异常或黏膜癌开展了监测、内镜治疗以及使用COX - 2抑制剂进行化学预防。巴雷特食管腺癌通过内镜检查和病理活检标本进行诊断。手术切除一直是主流治疗方法，但最近也开展了确定性或新辅助放化疗。
